Ho, Ching-Liang
Chao, Tsu-Yi
Chang, Chia-Lun
Lin, Hsuan-Yu
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
https://doi.org/10.1007/s40259-023-00639-w
Funding for this research was provided by:
Shanghai Henlius Biotech, Inc.
Article History
Accepted: 1 December 2023
First Online: 9 January 2024
Declarations
:
: This study was funded by Shanghai Henlius Biotech, Inc.
: Ching-Liang Ho, Tsu-Yi Chao, Chia-Lun Chang, and Hsuan-Yu Lin have no conflicts of interest that are directly relevant to the content of this article.
: The study was conducted in accordance with the International Council for Harmonisation guidelines on Good Clinical Practice and all applicable regulatory requirements, including the Declaration of Helsinki, and was approved by the Taipei Medical University-Joint Institutional Review Board (TMU-JIRB No.: N201710016), the Institutional Review Board, Tri-Service General Hospital (TSGHIRB No.: 2-106-01-024), and the Institutional Review Board, Changhua Christian Hospital (CCH IRB No.: 190613).
: All participants gave written informed consent prior to participation.
: Not applicable.
: The data generated during the current study are available from the corresponding author upon reasonable request.
: Not applicable.
: Conceptualization: C-LH; formal analysis and investigation: C-LH, T-YC, C-LC, H-YL; writing, original draft preparation: C-LH; writing, review and editing: T-YC, C-LC, H-YL; supervision: C-LH.